AbbVie gets option for argenx mAb

AbbVie Inc. (NYSE:ABBV) acquired an exclusive option from argenx N.V. (Euronext:ARGX) to license ARGX-115, a preclinical mAb against leucine-rich repeat containing 32 ( LRRC32; GARP), to treat cancer. argenx will be responsible for R&D through

Read the full 352 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE